The Babak Lab/LinkedIn
Jun 11, 2025, 08:31
Clinical Mondays: Tarlatamab Demonstrates Superior Outcomes in Relapsed SCLC – The Babak Lab
The Babak Lab shared a post on LinkedIn:
“Clinical Mondays: Tarlatamab Demonstrates Superior Outcomes in Relapsed SCLC: Phase 3 DeLLphi-304 Results
A global, randomized, phase 3 clinical trial (DeLLphi-304), sponsored by Amgen, evaluated the efficacy and safety of the novel DLL3-targeted bispecific T-cell engager Tarlatamab compared to standard chemotherapy (topotecan, lurbinectedin, or amrubicin) in patients with relapsed small-cell lung cancer (SCLC) following prior platinum-based treatment.
Key Findings:
Median overall survival: 13.6 months with Tarlatamab vs. 8.3 months with chemotherapy
Slower disease progression
Fewer severe adverse events: 54% vs. 80%
Improved patient-reported symptoms: less dyspnea and cough
Adverse Events:
The most common side effect of Tarlatamab was cytokine release syndrome (CRS), occurring in 56% of patients—mostly mild.
Neurologic adverse events were more frequent than with chemotherapy but generally mild.
Treatment discontinuation due to side effects occurred in 5% of Tarlatamab patients vs. 12% with chemotherapy.
Conclusion:
Tarlatamab offers an effective, better-tolerated second-line treatment option for SCLC following platinum therapy failure. The significant improvement in survival, symptom relief, and a more favorable safety profile underscore its potential to reshape the standard of care for relapsed small-cell lung cancer.Further trials are underway to evaluate Tarlatamab in earlier treatment settings.Link to the full article can be found in the comments section.”
Maria Babak, Assistant Professor at City University of Hong Kong, shared a post on LinkedIn by The Babak Lab, adding:
“The new results in SCLC treatment are notable. Tarlatamab represents another valuable option for patients facing limited choices.”
More posts featuring The Babak Lab.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 11, 2025, 07:35
Jun 11, 2025, 07:21